Source comparison
BPC-157 Research Sleep Considerations: Rodent vs. Human Comparison
Circadian Phase Nocturnal (active during dark cycle). Rest during light cycle Diurnal (active during light cycle). Rest during dark cycle Reverse timing recommendations: human rest-phase dosing = evening; active-phase dosing = morning Half-Life ~4 hours in rat
This comparison does not assign a generated winner or score.
- Circadian Phase
- Nocturnal (active during dark cycle). Rest during light cycle
- Diurnal (active during light cycle). Rest during dark cycle
- Reverse timing recommendations: human rest-phase dosing = evening; active-phase dosing = morning
- Half-Life
- ~4 hours in rats and mice
- Estimated 6–8 hours in humans (extrapolated from pharmacokinetic modeling)
- Human protocols may sustain once-daily dosing where rodents require twice-daily
- GABA Receptor Density
- Higher hippocampal GABA(A) density relative to body size
- Lower relative density but similar regional distribution
- Rodent models may show exaggerated sleep architecture changes vs. human subjects
- GH Secretion Window
- Peaks during early rest phase (first 2 hours post-lights-on for nocturnal species)
- Peaks during first sleep cycle (90–120 minutes post-sleep onset)
- Align dosing 1–2 hours before expected GH pulse for maximal anabolic synergy
- Sleep Architecture Sensitivity
- REM latency and NREM distribution shift within 24–48 hours of dosing changes
- Sleep changes may take 3–5 days to manifest due to slower metabolic adaptation
- Longer stabilisation period required in human trials before assessing steady-state effects
- Professional Assessment
- Rodent protocols require strict light-dark cycle control and consistent dosing relative to circadian phase. Timing variance introduces 25–40% noise in metabolic and behavioural outcomes.
- Human protocols must account for individual chronotype variation and sleep debt. BPC-157's effects on sleep may be masked or amplified depending on baseline sleep quality. Pre-study sleep screening is essential to control for confounders.